SCHEMBL3362085

SCHEMBL3362085

CN1CCCN(c2cncc(-c3ccc(/C=C4\SC(=O)NC4=O)c(F)c3)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 10/20 0.47
PIM1 P11309 6/20 0.47
CSNK2A2 P19784 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
PIM3 Q86V86 4/20 0.41
FLT3 P36888 2/20 0.41
DYRK1A Q13627 2/20 0.41
IGF1R P08069 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
MPL P40238 1/20 0.39
HIPK2 Q9H2X6 1/20 0.38
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3362086 1.00 PIM2 (0.47) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL13035905 1.00 PIM2 (0.47) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL3362165 0.92 PIM1 (0.49) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL3362170 0.92 PIM1 (0.49) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL3362769 0.89 PIM2 (0.48) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL3362773 0.89 PIM2 (0.48) PIM2PIM1CSNK2A2CSNK2A1CYP11B1
SCHEMBL12989801 0.84 PIM2 (0.62) PIM2PIM1CSNK2A2CSNK2A1PIM3
SCHEMBL3366675 0.84 PIM2 (0.62) PIM2PIM1CSNK2A2CSNK2A1PIM3
SCHEMBL3366668 0.84 PIM2 (0.62) PIM2PIM1CSNK2A2CSNK2A1PIM3
SCHEMBL3363323 0.83 PIM2 (0.44) PIM2PIM1CSNK2A2CSNK2A1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIM2 1/4885PIM1 2/4885CSNK2A2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.